甲狀腺疾病治療市場 - 按藥物類型（左旋甲狀腺素、碘塞羅寧、咪唑類化合物、BETA-阻斷劑）、疾病（甲狀腺功能減退症、甲狀腺功能亢進）、給藥途徑、配銷通路- 全球預測（2024 - 2032）

由於全球甲狀腺疾病（包括甲狀腺功能減退症、甲狀腺功能亢進症和甲狀腺癌）盛行率不斷上升，預計 2024 年至 2032 年甲狀腺疾病治療市場規模的複合年成長率將達到 3.9%。根據《柳葉刀》報道，甲狀腺疾病影響全球約 2 億人。碘缺乏、自體免疫疾病、遺傳傾向和生活方式改變等因素導致甲狀腺疾病的高發生率，尤其是在老年族群。隨著甲狀腺健康意識的增強和診斷能力的提高，越來越多的人尋求醫療協助。

醫療技術和治療的進步正在推動甲狀腺疾病治療的創新。標靶治療、放射性碘治療、微創手術技術、精準醫療等新的治療手段正在為患者提供更合適、更有效的治療。新診斷工具和生物標記的發展也使得甲狀腺疾病的早期診斷和監測成為可能，同時促進及時介入和改善患者的治療結果。

甲狀腺疾病治療產業分為藥物類型、疾病、給藥途徑、配銷通路和區域。

根據藥物類型，預計到 2032 年，BETA 受體阻斷劑領域的市場規模將出現大幅複合年成長率，因為它能有效控制與甲狀腺功能亢進相關的症狀。 BETA-受體阻斷劑，如普萘洛爾和阿替洛爾，透過阻斷過量甲狀腺激素對心血管系統的影響，有助於緩解心悸、顫抖和焦慮等症狀。當透過藥物、放射性碘治療或手術解決甲狀腺功能亢進的根本原因時，這些藥物還可以緩解症狀。

由於甲狀腺機能亢進疾病在全球的盛行率不斷增加，預計 2024 年至 2032 年期間，甲狀腺疾病治療產業將顯著成長。甲狀腺功能亢進以甲狀腺過度活躍為特徵，可引起心跳加速、體重減輕和焦慮等症狀，同時嚴重影響患者的生活品質。甲狀腺功能亢進的醫療干預措施，包括藥物、放射性碘治療和手術，對於控制症狀、使甲狀腺激素水平正常化和預防併發症也變得越來越必要。

由於醫療基礎設施的快速擴張和醫療服務的普及，預計到 2032 年，亞太地區甲狀腺疾病治療產業將以可觀的速度成長。由於缺碘、生活方式的改變和意識的提高，該地區甲狀腺疾病的盛行率很高，導致對甲狀腺功能減退症治療的高需求，刺激了該地區市場的擴張。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 甲狀腺疾病盛行率增加
    • 藥物製劑技術進步
    • 增加醫療保健支出
  • 產業陷阱與挑戰
    • 治療的副作用和併發症
    • 嚴格的監管場景
• 成長潛力分析
• 技術景觀
• 監管環境
• 波特的分析
• PESTEL分析

第 4 章：競爭格局

• 介紹
• 公司市佔率分析
• 競爭定位矩陣
• 戰略展望矩陣

第 5 章：市場估計與預測：按藥物類型，2021 - 2032

• 主要趨勢
• 左旋甲狀腺素
• 碘塞羅寧
• 丙基硫氧嘧啶
• 咪唑類化合物
• BETA-受體阻斷劑
• 其他藥物種類

第 6 章：市場估計與預測：按疾病分類，2021 - 2032 年

• 主要趨勢
• 甲狀腺功能低下症
• 甲狀腺功能亢進症

第 7 章：市場估計與預測：按管理途徑，2021 - 2032 年

• 主要趨勢
• 口服
• 靜脈
• 其他給藥途徑

第 8 章：市場估計與預測：按配銷通路分類，2021 - 2032 年

• 主要趨勢
• 批發商/分銷商
• 零售連鎖店
• 網上發行
• 其他分銷管道

第 9 章：市場估計與預測：按地區，2021 - 2032

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 歐洲其他地區
• 亞太地區
  • 日本
  • 中國
  • 印度
  • 澳洲
  • 韓國
  • 亞太地區其他地區
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地區
• 中東和非洲
  • 沙烏地阿拉伯
  • 南非
  • 阿拉伯聯合大公國
  • 中東和非洲其他地區

第 10 章：公司簡介

• Abbott Laboratories
• AbbVie Inc.
• Aspen Pharmacare Holdings Limited
• Glenmark Pharmaceuticals Ltd.
• Lannett Company, Inc.
• Merck & Co., Inc.
• Mylan N.V.
• Novartis AG
• Pfizer Inc.
• Sun Pharmaceutical Industries Limited

Thyroid gland disorder treatment market size is expected to register 3.9% CAGR between 2024 to 2032, driven by the increasing prevalence of thyroid disorders worldwide including hypothyroidism, hyperthyroidism, and thyroid cancer. As per Lancet, thyroid diseases impact approximately 200 million individuals globally. Factors, such as iodine deficiency, autoimmune diseases, genetic predisposition, and lifestyle changes are contributing to the high incidence of thyroid diseases especially in the elderly population. With the increasing thyroid health awareness and improving diagnostic capabilities, more individuals are seeking medical help.

Advancements in medical technology and treatment are driving innovations in the management of thyroid diseases. New therapeutic approaches, including targeted therapy, radioiodine therapy, minimally invasive surgical techniques, and precision medicine are providing more appropriate and effective treatment for patients. The development of new diagnostic tools and biomarkers is also enabling the earlier diagnosis and monitoring of thyroid disease while facilitating timely intervention and improving patient outcomes.

The thyroid gland disorder treatment industry is divided into drug type, disease, route of administration, distribution channel, and region.

Based on drug type, the market size from the beta blocker segment is projected to observe substantial CAGR through 2032 as it is effective in managing the symptoms associated with hyperthyroidism. Beta-blockers, such as propranolol and atenolol help in relieving symptoms like heart palpitations, tremors, and anxiety by blocking the effects of excess thyroid hormone on the cardiovascular system. These drugs also provide symptom relief, when the root cause of hyperthyroidism is addressed, either through medication, radioactive iodine therapy, or surgery.

Thyroid gland disorder treatment industry from the hyperthyroidism disease segment is anticipated to record significant growth rate during 2024- 2032 due to the increasing prevalence of this condition worldwide. Hyperthyroidism, characterized by overactive thyroid glands, can cause symptoms including rapid heartbeat, weight loss and anxiety, while significantly affecting the quality of life of patients. Medical interventions for hyperthyroidism, including medication, radioactive iodine therapy and surgery, have also grown necessary to manage symptoms, normalize thyroid hormone levels and prevent complications.

Asia Pacific thyroid gland disorder treatment industry is predicted to grow at a decent rate through 2032, attributed to the rapidly expanding healthcare infrastructure and the increasing access to medical services. The strong prevalence of thyroid disease in the region due iodine deficiency, changing lifestyles and increasing awareness is contributing to the high demand for treatment of hypothyroidism, stimulating the regional market expansion.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360-degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of thyroid disorders
    • 3.2.1.2 Technological advancements in drug formulations
    • 3.2.1.3 Increasing healthcare expenditure
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Side effects and complications of treatment
    • 3.2.2.2 Stringent regulatory scenario
• 3.3 Growth potential analysis
• 3.4 Technological landscape
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Competitive positioning matrix
• 4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Levothyroxine
• 5.3 Liothyronine
• 5.4 Propylthiouracil
• 5.5 Imidazole-based compounds
• 5.6 Beta-blockers
• 5.7 Other drug types

Chapter 6 Market Estimates and Forecast, By Disease, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Hypothyroidism
• 6.3 Hyperthyroidism

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Oral
• 7.3 Intravenous
• 7.4 Other routes of administration

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Wholesalers/distributors
• 8.3 Retail chain
• 8.4 Online distribution
• 8.5 Other distribution channels

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 South Africa
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Abbott Laboratories
• 10.2 AbbVie Inc.
• 10.3 Aspen Pharmacare Holdings Limited
• 10.4 Glenmark Pharmaceuticals Ltd.
• 10.5 Lannett Company, Inc.
• 10.6 Merck & Co., Inc.
• 10.7 Mylan N.V.
• 10.8 Novartis AG
• 10.9 Pfizer Inc.
• 10.10 Sun Pharmaceutical Industries Limited